227 related articles for article (PubMed ID: 35061208)
21. 3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.
Gao H; Tian Q; Zhou Y; Zhu L; Lu Y; Ma Y; Feng J; Jiang Y; Wang B
Front Immunol; 2022; 13():904418. PubMed ID: 35774776
[TBL] [Abstract][Full Text] [Related]
22. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
23. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer.
Sun X; Zhang T
Front Genet; 2022; 13():1067254. PubMed ID: 36452159
[No Abstract] [Full Text] [Related]
24. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
25. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
26. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
27. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
28. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
29. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
30. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
31. MIF as a potential diagnostic and prognostic biomarker for triple-negative breast cancer that correlates with the polarization of M2 macrophages.
Chen M; Liu H; Hong B; Xiao Y; Qian Y
FASEB J; 2024 May; 38(10):e23696. PubMed ID: 38787620
[TBL] [Abstract][Full Text] [Related]
32. Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer.
Zhou Q; Xu J; Xu Y; Sun S; Chen J
Front Immunol; 2023; 14():1176647. PubMed ID: 37671167
[TBL] [Abstract][Full Text] [Related]
33. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
Craven KE; Gökmen-Polar Y; Badve SS
Sci Rep; 2021 Feb; 11(1):4691. PubMed ID: 33633150
[TBL] [Abstract][Full Text] [Related]
34.
Zhao M; Zhang Q; Song Z; Lei H; Li J; Peng F; Lin S
Transl Cancer Res; 2023 Jul; 12(7):1802-1815. PubMed ID: 37588742
[TBL] [Abstract][Full Text] [Related]
35. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
36. A risk model of 10 aging-related genes for predicting survival and immune response in triple-negative breast cancer.
Yang X; Sun Y; Liu X; Jiang Z
Cancer Med; 2022 Aug; 11(16):3182-3193. PubMed ID: 35297220
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
39. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
[TBL] [Abstract][Full Text] [Related]
40. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
